Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series C round brings bluebird bio $30mm

Executive Summary

A year after closing a $35mm Series B, bluebird bio LLC (known as Genetix Pharmaceuticals until last September; therapeutic gene transfer for cerebral adrenoleukodystrophy, beta-thalassemia, and sickle cell anemia) has raised $30mm in its Series C round. New investor Arch Venture Partners participated (and contributes a new board member) along with returning shareholders Third Rock Ventures, TVM Capital, Forbion Capital Partners, and Easton Capital Investment Group.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies